Gordon C. Hunt

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement

Thomas J. Savides, Michael Donohue, Gordon C. Hunt et al. · Gastrointestinal Endoscopy · 2007 · 160 citations

Oncology, Pancreatic Cancer, Medical Imaging +14

Yield of tissue sampling for submucosal lesions evaluated by EUS

Gordon C. Hunt, P SMITH, Douglas O. Faigel · Gastrointestinal Endoscopy · 2003 · 110 citations

Medical Imaging, Interventional Endoscopic Ultrasound, Histopathology +6

Rapid Growth Rates of Suspected Pancreatic Cyst Branch Duct Intraductal Papillary Mucinous Neoplasms Predict Malignancy

Wilson T. Kwong, Robert D. Lawson, Gordon C. Hunt et al. · Digestive Diseases and Sciences · 2015 · 92 citations

Rapid Growth Rates, Surgical Oncology, Tumoral Pathology +7

Low Rates of Malignancy and Mortality in Asymptomatic Patients With Suspected Neoplastic Pancreatic Cysts Beyond 5 Years of Surveillance

Wilson T. Kwong, Gordon C. Hunt, Syed M. Abbas Fehmi et al. · Clinical Gastroenterology and Hepatology · 2015 · 61 citations

Surgical Oncology, Pancreatic Cancer, Pancreatic Fluid Collection +8